Filter the latest scan's published facts — sector, size, yield, valuation — or rank them with a preset: cheapest, fastest growing, most profitable. Every view shows what is in the filings and prices; none ranks opportunity. The model behind the statuses showed no predictive power, and nothing here is a recommendation.
Scan of 2026-08-31 · 2,409 names scored · prices as of that date
Lowest valid-in-sector trailing valuation multiples today, latest scan: each name's sector percentiles on earnings yield, FCF yield, P/S, P/B, P/TBV and P/CFO, averaged (only the metrics valid in its sector — a REIT is never ranked by GAAP P/E here). “Cheapest” is a fact about trailing multiples versus sector peers, not a forecast that they re-rate.
Tested the unforgiving way: a composite ranking built from these same point-in-time filings (2017-01-31 to 2026-05-29) showed no measurable predictive power (mean IC 0.0168, t = 1.21), and its top quintile did not beat holding everything even before costs. Ranks like these describe today's record; they do not predict tomorrow's return.
284 names — page 4 of 6 · sector: Pharma & chemicals · Export CSV
| # | Ticker | Company | Sector | Cheap composite | P/E (trailing) | P/S (trailing) | FCF yield | Own 5y |
|---|---|---|---|---|---|---|---|---|
| 151 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Pharma & chemicals | 44.9 | — | — | -38.1% | +0.7σ |
Never the absolute multiple alone. A P/E of 9 is a fact; whether it is low depends on what you hold it against.
The five-year window is the empirically privileged one. Cheap against its sector and cheap against its own history are different claims, and a stock can be one without being the other — which is the whole reason both columns are shown rather than blended into a single score.
| 152 | DSGN | Design Therapeutics, Inc. Common Stock | Pharma & chemicals | 44.7 | — | — | -5.7% | +0.9σ |
| 153 | CGON | CG Oncology, Inc. Common stock | Pharma & chemicals | 44.2 | — | — | -2.4% | — |
| 154 | JBIO | Jade Biosciences, Inc. Common Stock | Pharma & chemicals | 43.9 | — | — | -9.5% | +0.5σ |
| 155 | VRTX | Vertex Pharmaceuticals Inc | Pharma & chemicals | 43.8 | 31.9× | 11.3× | 2.7% | −0.1σ |
| 156 | DTIL | Precision BioSciences, Inc. Common Stock | Pharma & chemicals | 43.6 | — | 4.4× | -29.8% | +1.0σ |
| 157 | AVIR | Atea Pharmaceuticals, Inc. Common Stock | Pharma & chemicals | 43.3 | — | — | -34.5% | −0.3σ |
| 158 | IRON | Disc Medicine, Inc. Common Stock | Pharma & chemicals | 43.1 | — | — | -6.7% | +0.4σ |
| 159 | DD | DuPont de Nemours, Inc. Common Stock | Pharma & chemicals | 43.0 | — | 8.1× | — | +4.0σ |
| 160 | TARS | Tarsus Pharmaceuticals, Inc. Common Stock | Pharma & chemicals | 42.9 | — | 6.0× | -1.0% | +1.0σ |
| 161 | MAZE | Maze Therapeutics, Inc. Common Stock | Pharma & chemicals | 42.8 | — | 7.9×FY* | -9.2% | — |
| 162 | QDEL | QuidelOrtho Corporation Common Stock | Pharma & chemicals | 42.7 | — | 0.4× | -16.2% | −2.0σ |
| 163 | ABCL | AbCellera Biologics Inc. Common Shares | Pharma & chemicals | 42.5 | — | 44.1× | -5.4% | +0.0σ |
| 164 | MBX | MBX Biosciences, Inc. Common Stock | Pharma & chemicals | 42.5 | — | — | -2.7% | — |
| 165 | WDFC | Wd-40 Co | Pharma & chemicals | 42.5 | 36.1× | 4.5× | 2.7% | +0.6σ |
| 166 | CGEM | Cullinan Therapeutics, Inc. Common Stock | Pharma & chemicals | 42.0 | — | — | -13.2% | +0.9σ |
| 167 | TGTX | TG Therapeutics, Inc. | Pharma & chemicals | 41.9 | 18.0× | 11.9× | -0.2% | +0.7σ |
| 168 | SDGR | Schrodinger, Inc. Common Stock | Pharma & chemicals | 41.8 | — | 5.7× | -10.2% | −1.0σ |
| 169 | ANRO | Alto Neuroscience Inc. | Pharma & chemicals | 41.8 | — | — | -5.1% | — |
| 170 | CUE | Cue Biopharma, Inc. | Pharma & chemicals | 41.6 | — | 2.5× | -29.6% | +0.6σ |
| 171 | CLYM | Climb Bio, Inc. Common Stock | Pharma & chemicals | 41.6 | — | — | -8.2% | +1.1σ |
| 172 | PRAX | Praxis Precision Medicines, Inc. Common Stock | Pharma & chemicals | 41.5 | — | — | -2.9% | +0.6σ |
| 173 | DMRA | Damora Therapeutics, Inc. Ordinary Shares | Pharma & chemicals | 41.5 | — | 408× | -1.5% | +1.1σ |
| 174 | ANAB | AnaptysBio, Inc. Common Stock | Pharma & chemicals | 41.4 | — | 7.1× | 0.3% | +1.5σ |
| 175 | AGIO | Agios Pharmaceuticals, Inc. | Pharma & chemicals | 41.3 | — | 30.3× | -19.2% | +0.3σ |
| 176 | NKTR | Nektar Therapeutics | Pharma & chemicals | 41.0 | — | 26.1× | -14.0% | +0.9σ |
| 177 | ELVN | Enliven Therapeutics, Inc. Common Stock | Pharma & chemicals | 40.6 | — | — | -1.9% | +0.6σ |
| 178 | TRDA | Entrada Therapeutics, Inc. Common Stock | Pharma & chemicals | 40.6 | — | 47.7× | -48.1% | −1.7σ |
| 179 | TKNO | Alpha Teknova, Inc. Common Stock | Pharma & chemicals | 40.6 | — | 9.2× | -2.4% | +0.8σ |
| 180 | AVBP | ArriVent BioPharma, Inc. Common Stock | Pharma & chemicals | 40.6 | — | — | -9.9% | — |
| 181 | PVLA | Palvella Therapeutics, Inc. Common Stock | Pharma & chemicals | 40.0 | — | — | -1.3% | +0.5σ |
| 182 | APGE | Apogee Therapeutics, Inc. Common Stock | Pharma & chemicals | 39.9 | — | — | -2.4% | — |
| 183 | LGND | Ligand Pharmaceuticals Inc. | Pharma & chemicals | 39.8 | 37.1× | 20.7× | 2.2% | −0.7σ |
| 184 | SPRB | Spruce Biosciences, Inc. Common Stock | Pharma & chemicals | 39.8 | — | — | -36.2% | +0.9σ |
| 185 | KNSA | Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares | Pharma & chemicals | 39.7 | 82.5× | 8.0× | 2.7% | +0.7σ |
| 186 | UPB | Upstream Bio, Inc. Common Stock | Pharma & chemicals | 39.7 | — | 108× | -38.9% | — |
| 187 | TECH | Bio-Techne Corp. | Pharma & chemicals | 39.4 | 103× | 9.3× | 2.0% | −0.4σ |
| 188 | IMNM | Immunome, Inc. | Pharma & chemicals | 39.1 | — | — | -6.6% | +0.5σ |
| 189 | XNCR | Xencor, Inc. | Pharma & chemicals | 39.0 | — | 20.7× | -9.4% | −0.3σ |
| 190 | KYTX | Kyverna Therapeutics, Inc. Common Stock | Pharma & chemicals | 38.9 | — | — | -29.3% | — |
| 191 | ORKA | Oruka Therapeutics, Inc. Common Stock | Pharma & chemicals | 38.8 | — | — | -2.0% | +1.2σ |
| 192 | DNLI | Denali Therapeutics Inc. Common Stock | Pharma & chemicals | 38.4 | — | — | -11.1% | −0.2σ |
| 193 | HROW | Harrow, Inc. Common Stock | Pharma & chemicals | 38.2 | — | 5.1× | 1.0% | +0.8σ |
| 194 | VIR | Vir Biotechnology, Inc. Common Stock | Pharma & chemicals | 38.2 | — | 26.9× | -25.5% | −0.3σ |
| 195 | FENC | Fennec Pharmaceuticals Inc. Common Stock | Pharma & chemicals | 38.1 | — | 8.4× | -1.4% | +0.1σ |
| 196 | ACOG | Alpha Cognition Inc. Common Stock | Pharma & chemicals | 37.8 | — | 18.6× | -15.0% | — |
| 197 | RGEN | Repligen Corp | Pharma & chemicals | 37.7 | 199× | 13.4× | 1.0% | +0.0σ |
| 198 | MRVI | Maravai LifeSciences Holdings, Inc. Class A Common Stock | Pharma & chemicals | 37.7 | — | 9.6× | -2.7% | −0.7σ |
| 199 | KRRO | Korro Bio, Inc. Common Stock | Pharma & chemicals | 37.6 | — | 46.9× | -39.2% | +0.5σ |
| 200 | TRVI | Trevi Therapeutics, Inc. Common Stock | Pharma & chemicals | 37.1 | — | — | -2.1% | +0.6σ |
"Cheap composite" is a 0–100 position among valid sector peers — the mean of the component metrics' sector percentiles. "—" means the scan published no figure, deliberately. "n/a — masked" means the metric is misleading in that name's sector (a REIT's GAAP P/E, a bank's FCF yield) — hover for the reason, which comes from the same sector-validity rules the composite itself respects. An FY tag marks a trailing-year figure built from an annual filing; hover for what that means.